Tesamorelin vs CJC-1295 with Ipamorelin

If you are trying to choose between a Tesamorelin + Ipamorelin stack and a CJC-1295 + Ipamorelin stack, the short answer is: they share the same helper (ipamorelin) but use two different growth-hormone-releasing hormone analogs with meaningfully different pharmacological profiles. Tesamorelin has a narrow, FDA-approved clinical evidence base; CJC-1295 does not. That difference matters when evaluating what the research actually supports.

What both stacks have in common

Both stacks combine a GHRH analog with ipamorelin, a synthetic pentapeptide that acts on the ghrelin receptor to trigger a short growth-hormone pulse without meaningfully raising cortisol, ACTH, prolactin, or other pituitary hormones. The 1998 characterisation study for ipamorelin confirmed this selectivity in animal models: even at doses more than 200-fold above the effective GH-releasing dose, ACTH and cortisol were not significantly elevated^[1]. That selectivity is why ipamorelin became the default GHRP pairing in community protocols.

The rationale for combining a GHRH analog with ipamorelin is synergy: the two act through different receptors (GHRH receptor and ghrelin receptor) and different intracellular pathways, producing a GH pulse larger than either compound alone in animal models. A review of GH secretagogue pharmacology notes that preserving this pulsatile pattern keeps natural negative feedback intact^[2].

What tesamorelin is and what it is approved for

Tesamorelin is a synthetic GHRH analog. The FDA approved it in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. That is the only FDA-approved indication. The EMA received a marketing-authorisation application but it was withdrawn in 2012^[3].

The clinical evidence behind that approval is specific and limited. The pivotal trials enrolled HIV patients with lipodystrophy-associated visceral fat accumulation. A randomised, placebo-controlled trial published in JAMA in 2014 by Stanley et al. (n=50) found that tesamorelin produced a mean reduction in visceral adipose tissue (VAT) of -34 cm² versus a gain of +8 cm² on placebo (net treatment effect -42 cm², P=0.005). Liver fat also fell modestly^[4]. Critically, subcutaneous fat was not meaningfully reduced in the pivotal studies; tesamorelin's effect is concentrated on visceral adipose tissue, not total body fat^[5].

What CJC-1295 is and what the evidence covers

CJC-1295 is a synthetic GHRH analog modified with a drug-affinity complex (DAC) that binds to serum albumin, extending its half-life to approximately 5.8 to 8.1 days^[6]. That is far longer than tesamorelin or unmodified GHRH (both of which have half-lives measured in minutes). A 2006 study by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism tested single doses of CJC-1295 in healthy adults and observed dose-dependent increases in mean GH concentrations of 2- to 10-fold for six or more days, and mean IGF-1 concentrations 1.5- to 3-fold for 9 to 11 days, with no serious adverse reactions at the doses studied^[6].

A companion 2006 study by Ionescu and Frohman found that CJC-1295 raised basal GH levels by approximately 7.5-fold and overall mean GH by 46%, while preserving the natural pulsatile pattern of GH secretion rather than abolishing it^[7]. Pulsatility preservation is often cited as a pharmacological advantage in community discussions.

What CJC-1295 does not have is a completed Phase 3 programme, an approved indication, or published data on body composition endpoints in humans. The two 2006 pharmacokinetic studies are the main human evidence. They characterise GH and IGF-1 elevation but do not measure fat mass, lean mass, or any other outcome that gym-focused users care about.

The body composition question: what the research does and does not support

The community interest in these stacks centres on visceral fat loss and muscle support. Tesamorelin has direct, clinical-trial evidence for visceral fat reduction in a specific population (HIV lipodystrophy). The effect is real and replicated. Whether that visceral fat reduction extends to people without HIV lipodystrophy is unknown; no controlled trial has enrolled a general fitness or gym population for tesamorelin^[5].

CJC-1295 produces sustained GH and IGF-1 elevation in healthy adults. Higher IGF-1 is associated with increased muscle protein synthesis and reduced fat in the general endocrinological literature, but the 2006 CJC-1295 studies did not measure body composition as an endpoint^[6]. The body composition benefit that users expect is inferred, not measured.

In short: Tesamorelin has a narrower but more directly measured clinical effect (visceral fat in HIV patients); CJC-1295 has a more sustained GH/IGF-1 signal with no body composition data at all. Neither has been tested in a controlled trial for the gym-population use case.

Half-life and dosing logistics

Tesamorelin has a short half-life (minutes) and is dosed subcutaneously once daily. CJC-1295 with DAC can be dosed weekly or less frequently because of its albumin-binding half-life of 5.8 to 8.1 days^[6]. Some practitioners prefer the once-daily pulsatile profile of tesamorelin; others favour CJC-1295's dosing convenience. No head-to-head trial has compared body composition outcomes between these protocols.

Regulatory status and supply risk

Tesamorelin (Egrifta) is FDA-approved and requires a valid US prescription for its approved indication. Outside that prescription, it is not legally accessible in the US. It has no marketing authorisation in the EU, EEA, or UK. Grey-market tesamorelin carries purity, identity, and contamination risks.

CJC-1295 and ipamorelin are both unapproved in every jurisdiction we cover. The FDA Pharmacy Compounding Advisory Committee reviewed ipamorelin in October 2024 but compounding eligibility review is not the same as drug approval^[8]. Both peptides are listed under the WADA Prohibited List under S2 (peptide hormones and releasing factors), which is relevant to any competitive athlete.

What we do not yet know

There is no head-to-head trial comparing tesamorelin and CJC-1295 on any endpoint. We do not know whether the visceral-fat reduction documented in HIV lipodystrophy patients generalises to people without that condition. We do not know whether the sustained IGF-1 elevation from CJC-1295 produces meaningful lean mass or fat-loss changes in healthy adults over a multi-month cycle. Long-term safety for either peptide outside the HIV lipodystrophy population is uncharacterised, including the oncologic risk associated with prolonged GH and IGF-1 elevation.

Where this lands

If your goal is visceral fat reduction specifically, tesamorelin is the only GHRH analog with direct clinical evidence for that endpoint, but that evidence comes from HIV lipodystrophy patients, not from the general population. CJC-1295 produces a longer-lasting GH and IGF-1 signal in healthy adults, which is well documented, but its body composition effects have not been measured in any controlled trial. Both stacks are built on unapproved grey-market compounds everywhere outside a tesamorelin prescription in the US. Before considering either peptide, talk to a clinician who can review your baseline labs, medical history, and the regulatory picture in your jurisdiction. See the tesamorelin, CJC-1295, and ipamorelin pages for the full regulatory detail.